MASSDEVICE ON CALL — Results from the one of the 1st in-human studies of transcatheter aortic valve implants proved that the devices remained durable and effective 5 years after treatment, researchers found.
Cardiovascular
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
Svelte treats 1st patient with Svelte Acrobat stent system
Svelte Medical Systems treated the 1st patient in its clinical study, evaluating the company’s Svelte Acrobat Integrated Delivery System in comparison with conventional coronary stent devices in treatment of patients with lesions eligible for direct stenting.
The Svelte coronary stent IDS is low profile and highly flexible, designed to streamline stenting and thereby reduce procedure time and cost, the company said.
Over-stenting doc submits to 10-year prison sentence
A Louisiana interventional cardiologist accused of performing heart procedures on patient unnecessarily began his 10-year prison sentence this month after years of attempting to appeal his verdict.
Dr. Mehmood Patel, 64, was convicted in 2009 of 51 counts of fraudulently billing Medicare and other insurance groups for medical procedures that were deemed unnecessary. Patel was given a 10-year prison sentence, which was to start in July 2009.
Hospital repays $2M to Medicare for unnecessary stenting | MassDevice.com On Call
MASSDEVICE ON CALL — A Pennsylvania hospital group associated with more than 140 cases of unnecessary stenting and angioplasties repaid almost $2 million in Medicare reimbursements to the federal government.
The Excela Health network reached an agreement with federal regulators to return the funds, which were collected for heart surgeries performed between 2009 and 2011, according to settlement documents made public this month.
St. Jude shareholders accuse leadership of hiding Durata flaws
Updated Dec. 13, 2012, at 3:30 p.m. with comment from St. Jude Medical.
A group of St. Jude Medical (NYSE:STJ) shareholders filed a lawsuit accusing the company and 3 executives of making "false and misleading statements" about the Durata heart implant wires.
Boston Scientific enrolls 1st patient in new biliary duct stenting trial
Medical device company Boston Scientific (NYSE:BSX) enrolled its 1st patient in a new study evaluating its WallFlex Biliary RX fully covered self-expanding stents, part of the WallFlex suite of stents which the company says "is the most frequently implanted biliary metal stent worldwide."
Sorin wins Japanese OK for heart valve
Sorin Group (BIT:SRN) said it plans to launch its Mitroflow heart valve in Japan now that a regulatory body there has approved its use.
The Japanese Pharmaceuticals and Medical Devices Agency OK’d the aortic pericardial heart valve, which is surgically implanted to replace the aortic valve in patients with aortic stenosis, according to a press release.
Edwards Lifesciences gains on affirmed earnings guidance, 2013 forecast | Wall Street Beat
Edwards Lifesciences (NYSE:EW) reinforced its guidance for the rest of 2012 and issued its forecast for next year ahead of its annual investor conference today at its headquarters in Irvine, Calif.
Boston Scientific launches Synergy stent trial
Boston Scientific (NYSE:BSX) said the 1st patient was enrolled in the Evolve II clinical trial of its Synergy drug-eluting stent, aiming to use the data to back applications for approval in the U.S. and Japan.
The Natick, Mass.-based medical device company’s everolimus-coated stent uses a bioabsorbable polymer designed to elute the drug for 3 months, leaving a bare platinum-chromium stent behind.
CardiAQ Valve closes $37M funding round
CardiAQ Valve Technologies said it’s closed a $37.3 million equity round led by OrbiMed Advisors and plans to use the cash to fund feasibility and CE Mark clinical trials for its transcatheter mitral valve implant.
"The dynamic nature of the mitral anatomy, combined with the challenges of percutaneous access, make true transcatheter mitral valve implantation 1 of the most technically demanding device development endeavors of my career," CEO Rob Michiels said in prepared remarks.
Edwards wins Chinese approval for Perimount mitral valve
Medical device giant Edwards Lifesciences (NYSE:EW) touted China State Food & Drug Administration approval for its Carpentier-Edwards Perimount replacement mitral heart valve, part of the Perimount suite of devices that Edwards says are "the world’s most frequently implanted valves for more than 30 years."